Rohto Pharmaceutical (4527) · FactTransition to a division of responsibilities between the chairman and president
Retirement of the Representative President and Change to Chairman and President
First written in FY2019-Q2. . Latest entry: FY2020.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Departure and Successor Appointment Following the Death of the Representative Director and PresidentA theme 14 companies write about · 1 as a headwind · 0 as a tailwind
3 other companies' latest entry also says "Other".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2020Transition to a division of responsibilities between the chairman and presidentAnnual report
「Representative Director Chairman Yamada Kunio (山田 邦雄) Representative Director President Sugimoto Masashi (杉本 雅史)」
From the chairman-and-president structure described in FY2019-Q2, the FY2020 status of the filing company shows Yamada Kunio (山田 邦雄) as Representative Director and Chairman and Sugimoto Masashi (杉本 雅史) as Representative Director and President. - FY2019-Q2First statedAnnual report
「Representative Director and President Chief Operating Officer (COO) Yoshino Toshiaki (吉野 俊昭) 31 July 2018 (Retirement due to death) Representative Director, Chairman and President Representative Director and Chairman Chief Executive Officer (CEO) Yamada Kunio (山田 邦雄) 9 August 2018」
This describes the change in the executive structure: Yoshino Toshiaki (吉野 俊昭) retired as Representative Director and President following his death on 31 July 2018, and Yamada Kunio (山田 邦雄) became Representative Director, Chairman and President on 9 August 2018.